Literature DB >> 3947749

Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors.

R G Andrews, J W Singer, I D Bernstein.   

Abstract

A monoclonal antibody, 12-8, prepared against KG-1a cells, recognizes an approximately 115-kd cell surface antigen and reacts with 3% to 4% of bone marrow cells, including most of the blast cells. The antigen is not expressed on peripheral blood cells. Marrow cells expressing 12-8 collected by fluorescence-activated cell sorting contained nearly all of the unipotent (CFU-GM, BFU-E) and multipotent (CFU-MIX) colony-forming cells. The isolated 12-8 positive marrow population also contained precursors of these colony-forming cells. In a two-stage long-term marrow culture system employing irradiated allogeneic marrow adherent cells, 12-8 positive cells produced both unipotent and multipotent colony-forming cells for ten weeks. Moreover, the output of colony forming cells substantially exceeded the input. Antibody 12-8 appears useful for analysis and possibly enrichment of hematopoietic progenitor cells that include colony-forming cell precursors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947749

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization.

Authors:  T Murohara; H Ikeda; J Duan; S Shintani; K i Sasaki; H Eguchi; I Onitsuka; K Matsui; T Imaizumi
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Combination of HOXB4 and Delta-1 ligand improves expansion of cord blood cells.

Authors:  Korashon L Watts; Colleen Delaney; R Keith Humphries; Irwin D Bernstein; Hans-Peter Kiem
Journal:  Blood       Date:  2010-10-04       Impact factor: 22.113

4.  Patents and innovation in cancer therapeutics: lessons from CellPro.

Authors:  Avital Bar-Shalom; Robert Cook-Deegan
Journal:  Milbank Q       Date:  2002       Impact factor: 4.911

5.  Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study.

Authors:  Carolyn L Treasure; Jerry Avorn; Aaron S Kesselheim
Journal:  Milbank Q       Date:  2015-12       Impact factor: 4.911

Review 6.  Beyond mere markers: functions for CD34 family of sialomucins in hematopoiesis.

Authors:  Sebastian George Barton Furness; Kelly McNagny
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  Localisation of the gene coding for the haemopoietic stem cell antigen CD34 to chromosome 1q32.

Authors:  S M Howell; H V Molgaard; M F Greaves; N K Spurr
Journal:  Hum Genet       Date:  1991-09       Impact factor: 4.132

8.  Inhibition of hematopoiesis by competitive binding of transcription factor PU.1.

Authors:  M T Voso; T C Burn; G Wulf; B Lim; G Leone; D G Tenen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

9.  The impaired number of circulating granulocyte/macrophage progenitors (CFU-GM) in human immunodeficiency virus-type 1 infected subjects correlates with an active HIV-1 replication.

Authors:  M C Re; G Zauli; G Furlini; S Ranieri; P Monari; E Ramazzotti; M La Placa
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

10.  Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells.

Authors:  M L Lozano; F Ortuño; F de Arriba; M C Rosillo; J Rivera; I Heras; V Vicente
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.